Endothelin Receptor Blockade Improves Cerebral Blood Flow-Mediated Dilation in a Mouse Model of Alzheimer’s Disease
Journal of Vascular Research · 2023 · 60 (5-6) · 273-282
DOI: 10.1159/000534614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vascular Research, online erschienen am 17.11.2023. Verfasst von Daniel Henrion und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université d'Angers, MITOVASC, CNRS UMR 6015, INSERM U1083, Angers, France. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Introduction
Cerebral blood flow (CBF) is reduced in patients with Alzheimer’s disease (AD). Flow-mediated dilation (FMD), which plays a key role in the regulation of blood flow, is attenuated by endothelin-1. We hypothesized that endothelin receptor blockade may improve CBF in AD.
Methods
We investigated cerebrovascular reactivity in a mouse model of AD (APP-PS1; 5-6-month-old male subjects). We assessed the in vivo response to normoxic hypercapnia and in vitro FMD in isolated cerebral and mesenteric resistance arteries before and after endothelin receptor blockade (bosentan).
Results
Normoxic hypercapnia increased basilar trunk blood flow velocity (+12.3 ± 2.4%; p = 0.006, n = 6) in wild-type (WT) mice but reduced blood flow in APP-PS1 mice (−11.4 ± 1.2%; p < 0.0001, n = 8). Bosentan (50 mg/kg, acute intraperitoneal injection) restored cerebrovascular reactivity in APP-PS1 mice (+10.2 ± 2.2%; p < 0.0001, n = 8) but had no effect in WT. FMD was reduced in the posterior cerebral artery of APP-PS1 compared to WT and was normalized by bosentan (1 μmol/L, 30 min, or 50 mg/kg/day for 28 days). FMD was similar in the mesenteric artery of APPS-PS1 and WT.
Conclusion
APP-PS1 mice exhibited cerebrovascular endothelial dysfunction. Acute and chronic blockade of endothelin receptors restored endothelial vasomotor function, suggesting a promising therapeutic approach to restoring cerebral vasoreactivity in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université d'Angers, MITOVASC, CNRS UMR 6015, INSERM U1083, Angers, France.
- University Hospital (CHU) of Angers, Angers, France.
- Université Paris Cité, Physiologie Clinique - Explorations-Fonctionnelles, AP-HP, Hôpital Lariboisière, Paris, France.
- Université Paris Cité, INSERM U1144, UFR De Pharmacie, Paris, France.
- Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
- Inserm U970, PARCC, Paris, France.
Zitieren
APA
Henrion, D., Bonnin, P., Vessieres, E., Guihlot, A. L., Iglarz, M., & Lévy, B. I. (2023). Endothelin Receptor Blockade Improves Cerebral Blood Flow-Mediated Dilation in a Mouse Model of Alzheimer’s Disease. Journal of Vascular Research, 60(5-6), 273-282. https://doi.org/10.1159/000534614
Vancouver
Henrion D, Bonnin P, Vessieres E, Guihlot AL, Iglarz M, Lévy BI. Endothelin Receptor Blockade Improves Cerebral Blood Flow-Mediated Dilation in a Mouse Model of Alzheimer’s Disease. Journal of Vascular Research. 2023;60(5-6):273-282. doi:10.1159/000534614
BibTeX
@article{Henrion2023,
author = {Henrion, Daniel and Bonnin, Philippe and Vessieres, Emilie and Guihlot, Anne-Laure and Iglarz, Marc and Lévy, Bernard I},
title = {Endothelin Receptor Blockade Improves Cerebral Blood Flow-Mediated Dilation in a Mouse Model of Alzheimer’s Disease},
journal = {Journal of Vascular Research},
year = {2023},
volume = {60},
number = {5-6},
pages = {273--282},
doi = {10.1159/000534614}
}
EUVIMED